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Abstract
Why does a constant barrage of DNA damage lead to disease in some individuals, while others
remain healthy? This article surveys current work addressing the implications of inter-individual
variation in DNA repair capacity for human health, and discusses the status of DNA repair assays
as potential clinical tools for personalized prevention or treatment of disease. In particular, we
highlight research showing that there are significant inter-individual variations in DNA Repair
Capacity (DRC), and that measuring these differences provides important biological insight
regarding disease susceptibility and cancer treatment efficacy. We emphasize work showing that it
is important to measure repair capacity in multiple pathways, and that functional assays are
required to fill a gap left by genome wide association studies, global gene expression and
proteomics. Finally, we discuss research that will be needed to overcome barriers that currently
limit the use of DNA repair assays in the clinic.
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1. Introduction
During the time it takes to read this sentence, it can be estimated that the reader's DNA will
incur on the order of 10 trillion DNA lesions. Left unrepaired DNA damage has the potential
to lead to mutant cells, dead cells and ensuing disease (Figure 1). The precise number and
type of DNA lesions formed varies from one individual to the next in part because of
differences in exposure and lifestyle, and also because of variation in metabolism and other
cellular processes. Many types of DNA damage, such as abasic sites, alkylation damage,
oxidative damage, mismatches, single and double strand breaks, result from normal
metabolic processes. Others are induced upon exposure to environmental agents. Among the
environmentally induced lesions are bulky DNA adducts, including heterocyclic amines
induced by compounds in cooked foods, cyclobutane pyrimidine dimers induced by
sunlight, alkylation damage from nitroso compounds in combustion products, and oxidative
damage and DNA strand breaks induced by ionizing radiation from cosmic rays and
radionuclides such as Radon gas. In addition, some environmental exposures such as arsenic
do not directly induce DNA damage, but are thought to increase DNA damage levels both
by inducing inflammation and by disrupting DNA repair (1-3) (4, 5).
Fortunately, human cells mount a robust response to DNA damage that includes at least 7
major DNA repair pathways that specialize in the repair of subsets of DNA lesions, namely
direct reversal (DR), mismatch repair (MMR), nucleotide excision repair (NER),
homologous recombination (HR), base excision repair (BER), single strand break repair
(SSBR), ,non-homologous end joining (NHEJ), and Fanconi Anemia DNA crosslink repair
(FANC) (Table 1). The relationship between DNA damage and DNA repair is complex; no
single pathway efficiently repairs all types of DNA lesions, some lesions are substrates for
more than one pathway, and evidence for extensive interactions among proteins involved in
distinct pathways continues to emerge (6-11). Mutations in DNA repair genes can have
profound consequences for disease risk. The classic example is that individuals with the
disease Xeroderma Pigmentosum (XP) are highly prone to skin cancer because they have
mutations in genes required for nucleotide excision repair (NER), which repairs bulky
lesions such as those induced by UV light. These individuals are at a 2000-fold higher risk
of skin cancer in sun-exposed skin (12). A variety of other diseases including neurological,
developmental and immunological disorders, as well as premature aging, are associated with
aberrant DNA repair in humans (Table 1) (13). Thus, it is clear that defective DNA repair
caused by mutations in repair genes represents a major disease risk factor, and genetic tests
are now available for the most common disease-associated mutations in DNA repair genes
(14).
Intuitively, one might expect that DRC in a given pathway should vary even among
individuals who do not have rare disease-associated mutations in key DNA repair genes,
perhaps due to common sequence variants and epigenetic heterogeneity across populations.
DRC might thus adopt a normal distribution among individuals with disease-associated
DNA repair defects (red curve in Figure 2A), as well as among apparently healthy
individuals in the general population (black curve in Figure 2A) (15). One might further
hypothesize, based simply on interpolation (Figure 2B), that those in the general population
falling to the left of the distribution would be at higher than average risk for disease, and that
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they might be candidates for personalized prevention schemes. It has been over two decades
since these ideas were articulated by Hsu (16), and by Grossman and Wei (15), and although
a wealth of evidence for interindividual DRC differences has since emerged from multiple
laboratories using various methods (Table 2), it seems fair to say that the intervening studies
have not yet resulted in personalized prevention efforts. Other possible relationships
between DRC and risk of disease must also be considered (Fig 2C-2F), and these will be
discussed below. Inter-individual variation in DRC might also account for differing
tolerance among cancer patients for cancer therapy with DNA damaging agents. Moreover,
the sometimes dramatic changes in DRC in cancer cells versus non-cancer cells might be
exploited for individualized treatment.
Over the last two decades, significant efforts have focused on testing the idea that measuring
DRC has the potential to inform medical and clinical practice. In this review, we discuss
major lines of evidence supporting the notion that there are significant interindividual
differences in DRC, and further, supporting the claim that such variations are indeed
associated with disease risk. We survey the experimental approaches used to measure DRC,
and discuss future work that will be needed for clinical translation of functional DRC
measurements.
2. Evidence for inter-individual differences in DRC from indirect
measurements
Genetics
XP was the first human cancer-susceptibility disease found to be associated with a DNA
repair defect, namely NER; direct in vivo DRC measurements in cells isolated from XP
patients provided the critical insight that a DNA repair defect was the cause of the disease
(17). Complementation studies identified numerous genes responsible for XP, providing the
foundation for predicting NER defects and associated disease indirectly from genotype
analysis. Thus DNA sequencing of well-characterized mutations in XP genes can be used to
predict impaired DRC and increased disease susceptibility. Subsequent research has
identified numerous other disease-associated rare gene mutations that cause severe defects in
the MMR, NER, HR, BER, SSBR, NHEJ, and FANC pathways (Table 1), as well as defects
in DNA damage surveillance (18) and tolerance pathways (19).
Common single nucleotide polymorphisms (SNPs) that are associated with disease have
been identified in genes in the DR, BER, MMR, NER, HR, and NHEJ pathways (recently
reviewed in (20)). In candidate gene association studies, SNPs in DNA repair genes have
been associated with increased or decreased risk of many cancers including lung, colorectal,
gallbladder, oral, breast, prostate, liver, ovarian, and laryngeal cancer, as well as lymphoma
and squamous cell carcinoma (20). Genome wide association studies (GWAS) have revealed
many additional lower penetrance disease-associated sequence variants using unbiased
computational approaches (21, 22), but surprisingly few of these turn out to be DNA repair
genes. This may be explained in part by the observation that the variants identified so far
explain only a small portion of disease heritability. As yet unidentified DNA repair variants
may contribute to the missing heritability if they are relatively rare but confer a relatively
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large risk increment. Variants in DNA repair genes that confer risk could also be missed if
they represent copy number variants or they have relatively small effects; further, gene-gene
interactions involving DNA repair gene variants may also be missed in GWAS studies due
to low statistical power (23). Moreover, most GWAS-identified variants are not located in
genic regions, but rather in intergenic regions that are presumably involved in gene
regulation. Increased sample sizes,better accounting for rare variants and structural variants,
and better understanding of the role of regulatory variants will likely increase the ability of
DNA sequence-based assessments to identify individuals with elevated disease risk. In
section 3, we will discuss in detail functional assays that may complement DNA sequence-
based predictors of DRC defects.
In addition to disease prevention, genome profiling for sequence variants in DNA repair
genes has the potential to enable personalized disease treatment (24); it is already clear that
SNPs in DNA repair genes can play a role in assessing a prognosis for patients being treated
for melanoma, pancreatic, esophageal, or non-small cell lung cancer. SNPs in the following
DNA repair genes have been associated with the response of patients to cancer therapy:
MGMT, XPA, XPC, XPD, XPE, XPG, ERCC1, ERCC3, XRCC1, XRCC2, and XRCC3
(25-32). Polymorphisms in some DNA repair genes, such as ERCC1 and XPD, have also
been associated with increased cancer therapy toxicity (33), and MGMT polymorphisms are
associated with increased risk of myelodysplastic syndromes following treatment with
alkylating agents (34).
Major advantages of genomic profiling include the breadth of data that can be obtained for
relatively small (and steadily decreasing) investment of resources using next generation
sequencing (DNAseq), conceptual simplicity, and the universality of the approach;
standardized sequencing procedures foster high inter-laboratory reproducibility (35). An
important limitation of studies that aim to make predictions based on DNA sequence is that,
with the possible exception of CpG methylation specific PCR (MSP), one cannot know a
priori how well the gene with which the sequence variant has been associated is actually
expressed; indeed differential allelic gene expression is common (36). In this regard genome
sequence based assays may be regarded as the least direct means of measuring function
(Figure 3).
Transcriptional profiling
Transcriptional profiling has revealed that DNA repair gene expression has important
consequences for disease biology. For example, studies have identified prognostic gene
expression signatures in cancer cells that correlate with breast cancer survival (37, 38),
breast cancer recurrence (39), and lung cancer survival (40). Tumor gene expression profiles
that include DNA repair genes and correlate with cancer therapy response have also been
identified (41), and in some cases tumor expression of a single DNA repair gene correlates
with treatment efficacy (42-44). Moreover, gene expression profiling has been used to
identify bleomycin-induced changes in DNA repair gene expression that predict bleomycin
sensitivity, and low level radiation induced changes in DNA repair gene expression in (non-
cancerous) human lymphocytes that can be used as biomarkers for occupational exposure to
ionizing radiation (45, 46). An additional study in human lymphocytes demonstrated an
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inverse correlation between radiosensitivity measured by a G2 challenge assay and
expression of the NFKB gene; this study also showed an association between
radiosensitivity and breast cancer risk (47).
One study with human lymphoblastoid cell lines revealed that expression of a set of just 48
genes was sufficient to predict sensitivity to MNNG (48), an alkylating agent that generates
the same spectrum of DNA lesions as the chemotherapeutic drugs temozolomide,
dacarbazine, procarbazine and streptozotocin (49). These findings were important in several
respects; first it was possible to predict MNNG sensitivity in cells derived from apparently
healthy individuals using a small set of basally expressed genes, supporting the notion that
gene expression patterns could be used to help predict how tumor cells will respond to
therapy. Second, there were large variations in sensitivity to two different DNA kinds of
alkylating agents, and it was subsequently shown that sensitivity to one agent did not
accurately predict sensitivity to a second DNA damaging agent, indicating a unique response
to each agent (50). One of the predictive transcripts for MNNG sensitivity encodes the
methylguanine DNA methyltransferase (MGMT) protein that repairs O6-alkylguanine DNA
lesions by DR. This might be expected, since O6-methylguanine is one of the most toxic
lesions generated by MNNG. However, MGMT expression alone was a much weaker
predictor than expression of the combined set of 48 genes, indicating that sensitivity to DNA
damaging agents reflects the integration of numerous biological pathways. The other 47
genes included at least one other known DNA repair gene (MUTYH), and it is possible that
the other genes identified in this study affect DRC in ways that have yet to be established.
A major strength of gene expression profiling is the relatively new ability to complement or
replace quantitative real time PCR (qPCR) and microarray gene expression assays with next
generation RNA sequencing (RNAseq) to generate very accurate data assessing genome
wide expression levels, along with splicing information, at steadily falling costs. However,
as with genomic DNA sequencing analysis, gene expression profiling is limited because it
remains a relatively indirect measure of function; the presence of a transcript does not
guarantee that the translation product will be correctly folded, active, appropriately modified
and localized to the correct cellular compartment.
Mutagen sensitivity assays
Mutagen sensitivity assays, using mutagen-induced chromosome and chromatid breaks, can
also provide an indirect assessment of DRC phenotype (16, 20, 51). Epidemiological studies
comparing the response of lymphocytes to mutagens including bleomycin, UV-light, and
benzopyrene diol epoxide (BPDE) have revealed increased sensitivity to mutagen-induced
chromosomal aberrations in lymphocytes from individuals with cancer versus lymphocytes
from healthy individuals. This has been borne out in patients with cutaneous melanoma,
basal cell carcinoma, squamous cell carcinoma of the head and neck, plus patients with lung,
breast and bladder cancers (51). Of particular interest, a prospective study found that higher
bleomycin sensitivity of lymphocytes (>0.5 chromatid breaks per cell) from patients with
head and neck cancer was associated with an elevated risk (hazard ratio of 1.38) of
developing second, unrelated primary tumors as well as recurrence of the original cancer
(52); importantly the blood cells were drawn before development of second primary or
Nagel et al. Page 5
DNA Repair (Amst). Author manuscript; available in PMC 2015 July 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
recurrent tumors. A second prospective study found a significant association between
bleomycin sensitivity in lymphoblastoid cell lines and combined risk of prostate, lung,
colorectal and ovarian cancers in the patients from whom the cells were derived (53).
However, this study found no significant associations between cancer risk and several other
measures of DRC, including BPDE sensitivity, endogenous DNA damage levels measured
by comet assays, or host cell reactivation of UV-irradiated plasmids (comet and host cell
reactivation assays are discussed in detail below). These negative results may reflect the
small sample size and the focus on a limited number of DNA repair pathways.
A major advantage of mutagen sensitivity assays is that, by measuring the response of whole
cells to specific mutagens of interest, they integrate biological complexity, such as SNPs,
gene expression, epigenetics, protein folding and cell cycle checkpoint activation pathways
that may not be accounted for by other methods of measuring DRC. On the other hand, it
should be noted that a shortcoming of mutagen sensitivity assays is that they do not provide
specific mechanistic information with regard to the identity of the genotoxic lesion or the
pathways responsible for potentially defective repair, and they are relatively labor intensive.
3. Complications associated with indirect measurements of DRC
exemplified by a simple repair pathway
The challenges associated with making accurate indirect DRC measurements can be
illustrated by considering the performance of available methods for estimating MGMT
activity; this protein essentially represents a one-protein DNA repair pathway. SNPs that
may lead to MGMT defects have been associated with increased risk of some cancers, and
better prognosis following chemotherapy with alkylating agents, as might be expected if the
SNP leads to inefficient DNA repair (32). However, there are many examples of cancer cells
in which MGMT is epigenetically silenced due to promoter hypermethylation (43, 54, 55); in
these cases the sequence of the MGMT gene would be irrelevant to prognosis because the
gene is not expressed. Thus, information about promoter methylation and/or gene expression
may be needed to complement information obtained from DNA sequencing.
Epigenetic MGMT silencing due to promoter CpG hypermethylation in tumors has been
detected by methylation-specific PCR methods and shown to correlate with the efficacy of
cancer treatment with O6-MeG generating chemotherapeutic agents such as temozolomide
or dacarbazine (56). Nevertheless, even a combination of SNP data and promoter
methylation status may fail to predict function (and therefore clinical outcome) for several
reasons. MGMT methylation status is sometimes not predictive of transcript levels (57, 58),
and transcript levels are not informative unless the transcripts are translated and the protein
stably folded and localized to the nucleus. For example, a significant fraction of the human
MGMT protein is inactive in some cells (59), possibly due to posttranslational modifications
(60). Furthermore, environmental exposures can alter the activity of DNA repair proteins,
including MGMT (1, 2, 61). These phenomena may not be detected by the available indirect
measurements of MGMT activity.
A defect in protein localization could also confound DRC assays. Mitochondria-associated
OGG1 protein and activity levels are higher in the livers of old mice and in presenescent
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human fibroblasts compared to young mice and replicating human fibroblasts, respectively.
However, a significant fraction of OGG1 remains inactive and sequestered in the
mitochondrial outer membrane and intermembrane space, leading to accumulation of
unrepaired oxidized bases in the mitochondrial DNA (62). An age-related localization defect
was also observed for the mitochondrial uracil-DNA glycosylase (UNG) (62). A potential
analogous localization defect for MGMT (or any other DNA repair protein) could be
difficult to predict from the DNA sequence, and would not be detected by in vitro activity
assays performed on whole cell lysates. In general, relatively laborious
immunohistochemistry and subcellular fractionation techniques are required to detect
protein localization defects.
In this section we have principally highlighted some of the pitfalls associated with making
indirect measurements of DRC in the context of the simple one-protein MGMT pathway,
and one might anticipate even more complex challenges for indirect measures of DRC in
pathways that involve multi-protein complexes and multiple enzymatic steps (63-72). A
major strength of in vivo functional DNA repair assays is the ability to integrate the
complexity described above to reflect, as closely as possible, repair of genomic DNA
damage. The next section discusses recent technological advances for making direct DRC
measurements.
4. Evidence of inter-individual DRC differences from direct (functional)
measurements
There are numerous methods for measuring DNA repair directly, and each has its strengths
and weaknesses (Table 2). Some of the earliest protocols for measuring DRC, such as
unscheduled DNA synthesis, removal of radiolabeled alkylation damage from genomic
DNA (73, 74), and methods using antibodies specific for DNA lesions including BPDE, 8-
oxoG, O6-MeG, pyrimidine dimers and cisplatin adducts (75), hold the advantage of
measuring repair of genomic DNA in intact cells. While these assays have been used to
detect a 3-5 fold range in inter-individual DRC (76, 77), they are relatively labor-intensive
thus inhibiting their application to large-scale studies.
Activity assays with cell lysates
Pathway-specific DNA repair activity analyses in cell lysates have yielded considerable
insight into inter-individual variation in DRC. An advantage of these assays is that because
they measure levels of functional protein, they integrate much of the biological complexity
that might confound indirect measures of DRC (Fig. 3); indeed a low correlation between
enzymatic activity and mRNA levels has been documented in some cases (78). Quantitative
in vitro functional assays have been developed for various steps of BER (79-83), MMR (84),
DR of alkylation damage by MGMT (85), NER (86), NHEJ (87), cross-link repair (88), and
HR (89).
In vitro assays with cell-free extracts prepared from human lymphocytes have so far been
used to measure inter-individual differences in MGMT activity and in the efficiency of
several key steps in the BER pathway. These studies revealed an approximately 10-fold
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variation in MGMT activity (90), a 10-fold variation in activity of alkyladenine DNA
glycosylase (AAG, a.k.a. MPG) (49, 78, 91, 92) that initiates BER of several types of
alkylation damage, and a 3-fold interindividual variation in activity of 8-oxoguanine DNA
glycosylase (OGG1) (78) that initiates repair of oxidative DNA damage. Measurements of
the subsequent BER steps has revealed a 1.9-fold to 2.5-fold variation in AP endonuclease
activity (79, 82), 1.3-fold variation in subsequent polymerase beta dependent gap filling
(82), and 3.4-fold variation in DNA nick ligation (82).
Although cell-free assays are quantitative and permit specificity with regard to the type of
lesion being repaired, they have some limitations. The disruption of cells necessary for cell-
free analyses can lead to dissociation of protein complexes and protein unfolding, or can
mask defects in protein localization that would be detected using an in vivo assay. Similarly,
the assay buffers may fail to reflect the in vivo intracellular environment. In addition, the
substrates, typically naked short oligonucleotides, may not fully represent the complexity of
repair in chromatinized DNA.
Comet Assays
Comet assays provide a powerful means of measuring endogenous DNA damage, induced
DNA damage, and repair of DNA damage in genomic DNA in live cells (93). The assay is
named for the comet-like appearance of DNA after single cell gel electrophoresis, before
and after treatment with DNA damaging agents; measuring the disappearance of DNA
damage following DNA damage induction enables estimates of DNA repair kinetics. Double
strand breaks are measured at neutral pH, whereas single strand breaks are measured under
alkaline conditions that dissociate DNA strands. Cells may be treated with ionizing radiation
or bleomycin, which directly induce strand breaks, or agents such as UV-light, BPDE,
peroxides, and alkylating agents that induce DNA lesions that can be converted into strand
breaks upon processing in vivo by DNA repair machinery (94, 95). Genomic DNA base
damage levels can also be measured using the alkaline comet assay following treatment of
permeabilized gel-embedded cells with purified lesion-specific enzymes such as
Endonuclease III (thymine glycol), FPG and OGG1 (8-oxoG), T4 endonuclease V
(pyrimidine dimers), AlkA (alkylation damage such as 3-methyladenine), and UNG (uracil)
that convert their respective substrates to alkalai-labile abasic sites or to single strand breaks
(93).
Comet assays have been used in several studies with human lymphocytes to measure inter-
individual differences in DRC. One study demonstrated a 4-fold inter-individual variation in
BER of 8-oxoG and a 10-fold variation in NER of UV-induced damage (96). Differences in
DRC provide biological insight; reduced DRC relative to healthy individuals has been
associated with cancer risk in a number of studies (Table 2). An approximate 2-fold increase
in endogenous DNA damage (suggestive of reduced DRC) has been observed in
lymphocytes from brain cancer patients, relative to healthy individuals (97); up to 2-fold
higher levels of bleomycin induced DNA damage have been observed in lymphocytes from
breast cancer patients (98); and modestly reduced repair of bleomycin-induced DNA
damage has been observed in lymphocytes from both breast cancer patients and non small
cell lung cancer patients relative to healthy controls (98, 99). Furthermore, reduced repair of
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hydrogen peroxide-induced DNA damage was found in lymphocytes from lung cancer
patients (100), and a 4-fold variation in the rate of repair for ionizing radiation induced
DNA damage was found, wherein lymphocytes from head and neck cancer patients were
more likely to exhibit slow repair (101). The aggregate data from these studies raise the
possibility that individuals with lower DRC are more prone to cancer, and might be
candidates for more aggressive cancer screening.
Finally, comet assays have also been used to show that lymphocytes from patients with
extreme reactions to radiation treatment, defined as grade 4 (102), repair ionizing radiation
induced DNA damage with slower kinetics than lymphocytes from normal responders (103).
This work suggests that it may be possible to use DRC assays to predict radiation sensitivity,
and to tailor treatment based on individual tolerance.
Until recently, the labor-intensive nature and large inter-laboratory variation in analysis of
comet assay data constituted a significant barrier to the application of the comet assay in
large studies. However, a chip-based comet assay with automated image analysis has opened
the door to such studies (104); the comet chip assay provides a high throughput platform that
significantly reduces the inherent noise in the conventional comet assay. The ability to
measure repair of a wide variety of types of genomic DNA damage on a single comet chip
represents a major step forward. A limitation of the assay is that while there are strategies
for extending the comet assay to measure many types of DNA damage, the methodology is
limited to the subset of DNA lesions that either induce strand breaks or induce damage that
can be converted to strand breaks.
Host Cell Reactivation Assays
Host cell reactivation (HCR) assays offer a powerful way to measure DRC in living cells.
The foundation of the assay lies in the ability of transcription blocking DNA damage to
impede expression of a transiently transfected reporter gene; repair restores transcription of
the reporter gene, which may encode enzymes such as chloramphenicol acetyltransferase
(CAT) and luciferase, or a fluorescent protein (105). A major strength of HCR assays,
stemming from the in vitro generation of damaged reporter plasmid DNA, is the ability to
measure the in vivo repair of specific DNA lesions in intact cells.
The same association between reduced DRC and cancer risk found using mutagen
sensitivity, comet and cell free assays, was also demonstrated in several epidemiological
studies using HCR assays. For most of these studies, reporter protein activity was measured
in cell lysates prepared from transiently transfected human lymphocytes. Early HCR assays
using UV-irradiated CAT reporter plasmids showed approximately a 10-fold range of inter-
individual differences in NER capacity, with a significantly lower average DRC in
lymphocytes from basal cell carcinoma patients compared to those from controls (106).
HCR assays making use of UV-irradiated CAT or luciferase reporters have revealed 10-20%
reduced DRC (relative to control) in lymphocytes from patients with either melanoma or
non-melanoma skin cancer (107, 108). In other studies, repair of plasmids damaged with
BPDE or the nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) was
reduced between 10 and 60% in lymphocytes from patients with lung cancer (109-112),
non-small cell lung cancer (113), breast cancer (114-116), squamous cell carcinoma of the
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head and neck (117, 118), and lung adenocarcinoma (112). Furthermore, DRC below the
control median was associated with an increased risk of cancer, with odds ratios ranging
from 1.5 to 5.7 (51). In further studies, lymphocytes from bladder cancer patients repaired
plasmids damaged with 4-aminobiphenyl with ~10% reduced efficiency (119), and ~10%
reduction in repair of plasmids alkylated with dimethyl sulfate was observed in lymphocytes
from patients with lung adenocarcinoma (112). Assessment of NER capacity from
apparently healthy individuals has also shown a 5.6 to 11-fold range of inter-individual
variation and an inverse correlation with age and adiposity (120, 121). A plasmid end-
joining assay found a statistically insignificant ~6% reduced average DRC in lymphocytes
from breast cancer patients, but the lowest DRC quartile was positively associated with
increased cancer risk (odds ratio 2.2) (122).
Additional HCR assays, including a few with fluorescent reporters that do not require cell
lysates for analysis have been developed for measuring HR (123, 124), MMR (125), BER
(126), NHEJ (127), inter-strand cross link repair (7, 128, 129) and repair of oxidative
damage (130, 131). A multiplexed fluorescence-based flow cytometric HCR assay (FM-
HCR) that uses different colored fluorescent reporter plasmids to measure repair of multiple
doses or multiple types of DNA damage in a single assay was recently developed (132).
FM-HCR is less labor intensive than HCR assays that require cell lysate preparation, and
uses DNA lesion-induced transcriptional mutagenesis to measure repair of specific DNA
lesions, such as O6-methylguanine and 8-oxoguanine, that are bypassed by RNA polymerase
and thus refractory to conventional HCR assays. An even higher throughput HCR assay that
uses deep sequencing to measure and sequence reporter transcripts (HCR-seq) was also
developed (132). While the epidemiological studies have so far been dominated by NER
reporters, the availability of reporters for additional pathways and high throughput HCR
assays should encourage future studies to examine multiple repair pathways.
HCR assays face some potential limitations. The repair of constitutively transcribed plasmid
DNA measured by HCR may not accurately reflect repair of genomic DNA. However, the
assays have been validated using a variety of cell lines and in primary human blood cells
with DNA repair defects caused by mutated and inactivated DNA repair genes. Importantly,
numerous epidemiological studies (discussed above) have confirmed that HCR assays can
reproducibly measure small DRC differences in primary human tissues that are associated
with disease. In further support of the notion that plasmid DNA transactions can be
reflective of genomic DNA transactions, it appears that plasmids are readily complexed into
a nucleosomal structure in human cells, i.e. they become chromatinized (133-136).
Moreover, plasmid DNA damage induces histone modifications that affect expression of
plasmid DNA (137), indicating a functional plasmid-chromatin structure.
5. The need for assays that measure DRC in more than one pathway
The majority of epidemiological studies that apply functional DRC assays have focused on a
single DNA repair pathway, namely NER. However, data continue to emerge in support of
the notion that DRC for more than one pathway will be required to gain maximal biological
insight. Here we consider several contexts in which multiple DNA repair pathways, or the
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multiple steps within a single pathway, interact to influence disease risk or the sensitivity of
cells and animals to DNA damaging agents.
Multiple repair defects and cancer
Treatment with SN1 type alkylating agents such as temozolomide and decarbazine generates
toxic O6-MeG lesions that are repaired by MGMT. MGMT deficient cells are thus generally
very sensitive to SN1 alkylating agents. However because the toxicity of O6-MeG lesions is
mediated by MMR (138, 139), MGMT deficient cells can become resistant to alkylating
agents if they acquire a MMR deficiency (140). This chemoresistance or tolerance
mechanism would confound efforts to predict treatment efficacy based on tumor MGMT
status alone, and suggests a need to measure both pathways for improved prognosis. A
second example where the status of two or more pathways determines the sensitivity of cells
is seen in the context of poly(ADP-ribose) polymerase (PARP) inhibitors. PARP is involved
in DNA single strand break repair, and PARP inhibition potentiates DNA damage-induced
cell death (141). In the absence of DNA damaging agents, cells can generally tolerate either
PARP inhibition or a defect in HR. However, because HR rescues the collapsed replication
forks generated when the replication machinery encounters a single strand break, treatment
of HR-deficient cells with PARP inhibitors leads to a synthetic lethality (141).
Polymorphisms in multiple DNA repair pathways or multiple steps within a pathway are
associated with elevated cancer risk. A study of non-small cell lung cancer patients revealed
small individual hazard ratios (up to ~1.4) for polymorphisms in genes involved in NER
(XPA, XPD, XPG), BER (XRCC1), and HR (XRCC2, XRCC3), but a larger hazard ratio for
patients with any combination of 4 or more polymorphisms in different genes within a
pathway or in different pathways (hazard ratio 1.8) (28). For pathways that involve more
than one repair protein, such as NER, there is potential for an additive or synergistic effect
of combining modest functional defects in multiple steps along the pathway. A recent
candidate gene association study revealed that SNPs in the NER genes XPG, XPD, XPA,
and XPE are associated with worse prognosis following skin cancer diagnosis; a hazard ratio
of 1.26 was calculated for individuals with a variant genotype in one of the genes, but the
hazard ratio increased dramatically for individuals with variants in 2 or 3 of these genes to
3.90 and 34.3, respectively (30).
Functional DRC measurements in multiple DNA repair pathways have also revealed higher
risk factors than measurements in any single pathway would indicate. A breast cancer study
found that combined NER deficiency (measured by an immunohistochemical assay for
BPDE repair) and NHEJ deficiency (measured by a plasmid repair assay) represented a
greater cancer risk factor (odds ratio 4.92) than deficiency in either pathway alone (odds
ratio 1.16) (77, 122). A second case control study of both OGG1 and AAG activities showed
that reduced OGG1 activity and elevated AAG activity were associated with a higher risk of
lung cancer, and most important, that a combined score for the two enzyme activities was
more strongly associated with cancer risk than either OGG1 or AAG activity alone (142).
Recently, this study has been extended to incorporate APE1 into an integrated DNA repair
score, termed “OMA” for OGG1, MPG (a.k.a AAG) and APE1; the OMA score varies over
a 20-fold range and associates even more strongly with risk of lung cancer (odds ratio 5.6
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comparing individuals with the lowest to highest tertile OMA scores) (143). These results
emphasize that measuring repair capacity in more than one pathway has the potential to
increase biological insight and reveal stronger correlations between DRC and disease risk. It
should be noted that the lower OMA scores correspond to lower levels of OGG1 and APE1
activity, but higher AAG activity, underscoring the fact that for some pathways high levels
of DRC are not always protective.
Imbalanced repair and toxic repair intermediates
Evidence for potentially harmful and tissue dependent effects from higher DRC levels has
emerged from the characterization of Aag-dependent alkylation sensitivity in cells and
animals. Aag deficiency has been associated with sensitivity to alkylating agents in mouse
embryonic stem cells, consistent with a relationship wherein risk (defined for this specific
example as the risk of cell death upon exposure to an alkylating agent) in one tissue
decreases with increasing DRC (Fig. 2b). However an unexpected phenotype was observed
in mouse models, wherein Aag deficiency leads to extreme alkylation resistance in certain
tissues (49), indicating, that for some tissues risk increases with increasing DRC (Fig. 2c).
Accordingly, overexpression of Aag leads to tissue-specific alkylation sensitivity in mice
(92).
A lack of proper coordination among multiple DNA repair steps (repair imbalance) has been
invoked to explain increased alkylation sensitivity in cells that overexpress Aag. Aag
overexpression leads to the accumulation of DNA repair intermediates (49, 144), which
include 5’-deoxyribose phosphate containing single strand breaks that can trigger
hyperactivation of PARP. This enzyme modifies numerous other proteins, including several
in DNA repair pathways (141, 145). PARP also facilitates both repair (SSBR and BER) as
well as a cell death pathway involving NAD and ATP depletion, and an energetic crisis
followed by cell death (146-148). Cells and whole animals that overexpress Aag but are
genetically deficient for PARP show a complete rescue of wild type sensitivity to alkylating
agents, confirming that SSB-stimulated PARP hyperactivation is responsible for
hypersensitivity (92).
It should be noted that this situation contrasts with pharmacological PARP inhibition that
generally leads to DNA alkylating agent sensitivity. The consequences pharmacological
PARP inactivation using inhibitors may differ from the consequences of genetic depletion
because inhibitors can induce formation of a stable 5’dRP:PARP:Inhibitor complex at SSBs
that inhibits DNA repair and blocks replication (149-151), potentially leading to double
strand breaks (152, 153). Thus PARP inhibition leads to alkylation hypersensitivity in cells
that accumulate SSBs, including cells that overexpress AAG (154), and polymerase beta or
ligase III deficient cells (155, 156).
SSBs also accumulate in cells from individuals with the neurodegenerative diseases
spinocerebellar ataxia with axonal neuropathy-1 (SCAN1) and ataxia oculomotor apraxia-1
(AOA1) (157). For SCAN1, abortive topoisomerase-I reactions lead to SSBs covalently
linked to the enzyme; SCAN1 patients are deficient for the TDP1 enzyme that hydrolyzes
the 3’-phosphotyrosyl bond between stalled topoisomerase-I and a SSB to facilitate repair. A
related enzyme, TDP2, hydrolyzes 5’-phosphotyrosyl bonds between topoisomerase-II and
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DNA at DSBs to facilitate NHEJ-dependent repair (158), and exhibits weak 3’-tyrosyl
phosphodiesterase activity (159), however TDP2 has not as yet been associated with disease.
AOA1 patients are deficient for APTX, an enzyme that catalyzes reversal of premature 5’-
adenylation at SSBs; although 5’adenylation is required for ligation of SSBs, if this
modification occurs in the absence of a free 3’ hydroxyl, ligation cannot be completed. It is
of particular interest that SCAN1 and AOA1 manifest as neurodegenerative diseases, but do
not predispose to cancer. To explain this disproportionate effect on terminally differentiated
neurons, it has been proposed that TDP1 and APTX may be redundant in proliferating cells
because alternative end processing factors and the HR pathway can resolve SSBs during
replication (157).
An additional example of a phenotype caused by the accumulation of repair intermediates
that depends on multiple DNA repair proteins, comes from a recent study implicating the
DSB repair protein WRN in long patch BER of adenine opposite 8-oxoguanine (A:8-oxoG)
(160). Cells deficient for WRN or polymerase λ are more sensitive than wild type to
oxidizing agents such as hydrogen peroxide, due to inefficient BER of oxidative damage.
However, WRN deficient cells and polymerase λ deficient cells that are also deficient for
MUTYH exhibit wild type sensitivity to oxidizing agents, suggesting that MUTYH leads to
toxic repair intermediates . Indeed, glycosylase mediated accumulation of toxic BER
intermediates has also been invoked to explain sensitivity to a variety agents including
alkylating agents (49, 144), ionizing radiation (161), and 5-fluorouracil (162).
Repair competition
Some DNA lesions are repaired by proteins from more than one of the canonical DNA
repair pathways shown in Table 1 and Table 2. Multiple pathways may either complement
or interfere with one another. For example, BER of 8-oxoG opposite cytosine is initiated by
one of several DNA glycosylases (OGG1, NEIL1 and NIEL2) (163). Moreover, it was
recently reported that proteins involved in transcription coupled NER (e.g. XPA, CSB and
RNA polymerase II), also participate in an 8-oxoG repair in actively transcribed DNA (9).
Another example of distinct repair proteins competing for the same lesions arises for highly
mutagenic etheno base lesions (164-166). Ethenocytosine (εC) can be bound by AAG but
not excised by it, and this binding interaction prevents repair by ALKBH2 (166) and
possibly TDG glycosylase. As a result, individual activity levels for AAG, TDG or
ALKBH2 would not provide a complete picture for the repair of εC base lesions. Finally,
although agents that form inter-strand cross-links (ICL) have been widely used as
chemotherapeutics, the detailed mechanisms of ICL repair are only now beginning to be
understood (167). Evidence exists for replication-dependent and replication-independent
ICL repair involving proteins from several DNA repair pathways including the FA, HR, and
NER pathways, as well as TLS polymerases (7, 8). Recent work shows that BER and MMR
play an epistatic role in mediating cisplatin sensitivity, implicating proteins from these
pathways in ICL repair as well (6, 10).
Immune dysfunction
Because immune function involves programmed induction of multiple types of DNA
damage, DNA repair proteins from multiple pathways also play a critical role in the immune
Nagel et al. Page 13
DNA Repair (Amst). Author manuscript; available in PMC 2015 July 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
system, and some DRC defects are associated with immunodeficiency (Table 1). Numerous
DSB repair proteins are required for V(D)J recombination, which takes place in both T and
B lymphocytes and is essential for the development of specialized antigenic receptors
known as T-cell receptors (TCR) and B-cell receptors (BCR), composed of an
immunoglobulin molecule and a CD79 moiety. The process is initiated by the Rag1 and
Rag2 recombinase enzymes that induce DSBs in specific recombination signal sequences
flanking V, D, and J gene units. These DSBs are then repaired by NHEJ. Consequently,
many human patients with NHEJ deficiencies also have V(D)J recombination defects and
suffer from a particular group of diseases known as severe combined immunodeficiencies
(SCID), in particular, radiosensitive SCID. SCID is characterized by impaired T and B
lymphocyte differentiation that is sometimes accompanied by deficiencies in other lineages
(168). Individuals with deficiencies in NHEJ proteins (DNA-PKcs (169), Artemis (170,
171), LigIV (172) and NHEJ1/XLF/Cernunnos (173)) consistently present some degree of
SCID.
Proteins from several DNA repair pathways are also involved in the terminal maturation of
B lymphocytes during which two additional stages of DNA modification take place after
VDJ recombination in order to increase the efficiency of the humoral response (174, 175).
First, class switch recombination (CSR) exchanges the immunoglobulin (Ig) constant region
to modify the Ig isotype (from IgM to IgG, IgA, etc.). In the second step, somatic
hypermutation (SHM) introduces sequence diversity into the Ig variable domain to provide
the potential for increased antigen affinity. Both CSR and SHM are initiated by the action of
activation-induced cytidine deaminase (AID). Within hotspots, AID deaminates cytosine to
uracil, creating U:G mismatches. CSR is induced when the BER protein UNG excises
closely opposed uracils that are further processed by APE1 to generate a DSB that triggers
processing by the HR machinery. U:G pairs escaping UNG recognition can go on to be
processed by the MMR machinery and subsequently form DSB in a yet unidentified manner
(176). The distinct process of SHM occurs by replication bypass of uracil (in the absence of
repair by MMR or BER) inducing C to A transversions, or by translesion polymerase bypass
of AP sites and gaps (generated by UNG and MMR proteins, respectively). As might be
expected from their involvement in the immune response, deficiencies in both BER and
MMR have been implicated in improper B-cell maturation; one of the autosomal forms of
CSR deficiency known as hyper-IgM (HIGM) syndromes has been ascribed to mutations in
the UNG gene (177). Similarly, three patients with deficiencies in the MMR protein PMS2
were shown to be deficient in CSR (178). Immunodeficiency syndromes are associated with
increased risk of cancer (179), it has been recently hypothesized that germline mutations in
genes involved in V(D)J recombination, SHM and CSR play a role in the lymphomagenesis
of diffuse large B cell lymphomas (180).
Our understanding of the role that DNA repair plays during normal lymphocyte maturation
continues to evolve as additional interactions between DNA repair pathways are discovered.
For example, recent work suggests that interactions between MMR proteins and the MBD4
DNA glycosylase may be important for efficient CSR (181). An intriguing possibility is that
the pronounced DNA repair defects associated with some severe immune disorders may
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presage discovery of milder immunodeficiency that can be attributed to modest defects in
multiple DNA repair pathways.
The diversity of disease states and sensitivity phenotypes associated with inefficient DNA
repair in more than one pathway, or in more than one step within a pathway, calls for more
studies that explore multiple repair activities. Recently accumulating data discussed above
suggest subtle defects in multiple DNA repair pathways might promote disease, raising the
prospect that multiplexed DRC assays could be of value in clinical diagnosis, prevention and
treatment of disease.
6. Current status of DRC measurements for prevention and treatment of
disease
A long-term goal that motivates many of the epidemiological studies discussed herein is to
eventually apply direct or indirect estimates of DRC to the personalized treatment or
prevention of disease. However current clinical practice is limited to diagnostics. Genetic
testing is available for known mutations in many of the genes associated with DRC defects
and disease, including BRCA1/2, MLH1, MSH2/6, p53, and MUTYH (14); individuals with
these mutations are advised to undergo more aggressive screening, and in some cases
prophylactic surgery. T-cell chromosome breakage or aberrations following treatment with
DNA damaging agents such as mitomycin C have been used as a diagnostic for Fanconi
Anemia (182), and UV-induced unscheduled DNA synthesis and sister chromatid exchange
assays have been used for the molecular diagnosis of XP and Blooms syndrome,
respectively (183). However, because they are labor intensive and/or expensive, both genetic
testing and cell-based assays are typically used only in cases where the disease is already
suspected either because of pronounced symptoms or a family history of disease.
DRC Estimates may be close to finding application in cancer treatment. Relationships
between DRC and improved tumor response to anticancer drugs have been reported for
MMR proficiency in cisplatin, alkylating agents, and 5-fluorouracil cancer chemotherapy
(140, 184-186). XRCC1 (BER) deficiency in tumors has been linked to cisplatin sensitivity
(44, 187); MGMT deficiency has been linked to temozolomide and BCNU sensitivity (188,
189), and HR deficiency to PARP inhibitor sensitivity (141). A limited study suggests that
functional assays could be useful for determining the maximum radiation dose that will be
tolerated by a patient (103). Thus, if individuals could be pre-identified as therapy resistant,
it may be possible to raise the treatment dose to improve efficacy. Despite these examples of
potential clinical applications, enthusiasm for the use of DRC measurements to guide
treatment decisions are dampened by concerns about assay standardization, assay
reproducibility, and the lack of prospective, randomized studies. As a result, although DRC
assays are used to retrospectively classify patients into good versus poor responders to
cancer therapy (28, 43, 53, 187, 190, 191), these assays are not used currently to influence
cancer patient management (20, 58, 192-197).
Nagel et al. Page 15
DNA Repair (Amst). Author manuscript; available in PMC 2015 July 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
7. What is needed going forward
To speed the translation of functional DRC assays from a laboratory tool to biomedical
applications, advances are needed in several areas. (i) Excepting a small number of
prospective studies (52, 53, 198), virtually all studies associating DRC defects with cancer
susceptibility have been retrospective, raising concerns that the observed DRC differences
may reflect changes subsequent to cancer diagnosis, or to cancer treatment. Similar levels of
DNA damage have been observed in lymphoblastoid cell lines derived before versus after
cancer diagnosis (198), suggesting that cancer development may not alter DRC. Moreover,
one line of evidence suggests that lymphocyte DRC may be altered in cancer patients due to
a systemic inflammatory response to the disease (199-203), and it is also possible that cancer
treatment affects DRC. There is thus a need for additional large prospective studies to
confirm that the DRC was a cause, rather than an effect, of the disease, and that subsequent
treatment did not cause long-term DRC changes. We advocate that as new studies are
initiated, cells from patients and their tumors should be cryopreserved such that live cells
can be recovered for the purpose of functional DRC assays. Currently such samples are most
often preserved for DNA, RNA and protein analyses, under conditions incompatible with in
vivo functional assays. (ii) To carry out large studies, high throughput quantitative assays
measuring DRC in multiple pathways are needed to maximize biological insight and
prognostic potential. Standardized quantitative assays will help overcome concerns about
reproducibility, an issue that is especially acute for assessments that are more subjective and
less quantitative DRC indicators, such as microsatellite instability (MSI), where labs use
different thresholds to distinguish MSI from microsatellite stability (204). (iii) The
complexity of the relationships between DRC, other pathways, genetics, epigenetics and
environmental exposure suggest that complementary approaches combining several of the
techniques described above and in Fig. 3 may be needed to provide a comprehensive
assessment of DRC. Collaborative projects using multiple approaches would be helpful for
determining which approach or combination of approaches yields the most robust DRC-
based disease prediction and diagnostic potential. (iv) The suitability of lymphocytes as a
surrogate tissue for DRC in other tissues requires additional testing. The numerous
epidemiological studies referenced above support the utility of measuring DRC in
lymphocytes to predict disease susceptibility, and some investigators have found strong
correlations between DRC in lymphocytes and other tissues (205), while others have not
(90). (v) DRC variation among tissues is underexplored. In both humans and mice, large
tissue-specific DRC variation has been measured for some pathways, indicating that it may
be necessary to measure DRC directly in the tissue of interest (92, 206, 207). For example,
DRC in liver cells might be most useful in assessing liver cancer risk; however the need for
an invasive biopsy represents a major barrier to tissue-specific DRC screening. A
particularly promising solution to this problem would be to generate cells representative of
various human tissues by differentiating induced pluripotent stem cells (iPS cells) generated
from skin fibroblasts that can be obtained from a single, relatively less invasive biopsy. The
commercial availability of multiple cell types from a single individual (including iPS cells)
together with advancing methods of generating iPS cells from primary tissues (208), make
an initial test this approach experimentally feasible. A long-term goal would be to develop
methods of measuring tissue-specific DRC variation in a variety of human cell types derived
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from a skin biopsy from each individual. (vi) Finally, mitochondrial DNA repair represents a
relatively understudied area, and given the severe health consequences of mitochondrial
DNA depletion (209), as well as accumulating evidence of relationships among
mitochondrial DNA damage, mitochondrial dysfunction and disease (210-215), it appears
likely that defects in mitochondrial DRC can also be linked to disease susceptibility.
8. Conclusions
The aggregate data from several decades of molecular epidemiology indicate that DRC
varies significantly among individuals, and that these variations associate with disease risk.
No single DNA repair pathway is universally representative of DRC in general, and the
effects of variation in repair efficiency at distinct steps or in separate pathways can combine
to produce surprising and sometimes counterintuitive phenotypes. There are many ways to
measure DRC. However each has its strengths and weaknesses. So far a lack of
standardization and clinical validation, together with the relatively low throughput and
labor-intensive nature of most methods of measuring DRC have precluded the application of
functional DRC assays for personalized disease prevention and treatment. However a recent
burst of technical advances, including the highly automated comet chip (104), a proof of
concept for integrating DRC in multiple pathways to calculate disease risk (143), and highly
multiplexed HCR assays (132), support the notion that measuring DRC could become
common clinical practice. To promote this transition, these emerging technologies should be
further developed, standardized and validated across multiple laboratories in large (ideally
prospective) epidemiological studies employing measurements of multiple DNA repair
pathways.
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Figure 1.
DNA damage, DNA repair, and disease. The canonical role of DNA repair is to protect cells
from death, mutation, and the inception of disease. As discussed in the main text, increasing
DNA repair can also have the opposite effect, inducing cell death because of the potential
accumulation of toxic repair intermediates. The environment and the physiology of the
individual enter this diagram at two points; both factors may may increase DNA damage, or
they may affect DRC either positively or negatively.
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Figure 2.
Potential consequences of DRC variability. a) Both intuition and experimental data point to
a distribution in DRC, shown here for a single pathway among healthy individuals (black
curve), and a multimodal distribution when disease states (red curve) are included; this panel
is inspired by a similar figure originally published by Grossman and Wei (15). b) The
simplest assumption is that a generic representation of risk (cell death, disease diagnosis or
mortality) will decrease as DRC increases. c) In some cases, such as when a level of
glycosylase initiates BER leading to an accumulation of intermediates that are more toxic
than the initial DNA damage, elevated DRC may be deleterious. d and e) In principle the
combined influence of factors driving the relationships in panels b,c could lead to more
complicated relationships between risk and DRC. f) The relationship between DRC and risk
may be represented as a complex landscape that depends on DRC in more than one pathway.
As discussed in section 5, multiple DRC defects can act synergistically, but can also produce
surprising and counterintuitive phenotypes.
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Figure 3.
Methods of assessing DRC and their limitations. The biological trajectory that runs from
genes to function includes numerous intermediate steps at which a given assay may fail to
predict the functional endpoint. The point along this trajectory at which a particular method
may fail is indicated by color-coded bars running from left to right. Although any of the
assays may accurately predict function, only functional (Comet and HCR) assays integrate
the complexity of this entire trajectory into their readout.
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Table 1
Human diseases associated with DNA repair deficiencies categorized by DNA repair pathway.
Repair pathway Primary Lesions Genes Associated with Disease Diseases Associated References
DR O6-meG MGMT - Esophageal, Lung Cancer (216)
MMR Mismatches, loops MSH2, MLH1, MSH6, PMS2 -Hereditary Non-Polyposis Colon Cancer
(HNPCC)
-Class Switch Recombination (CSR)
Defects
-T-cell non-Hodgkin's lymphoma (T-
NHL)
-Diffuse large B-cell lymphoma
(DLBCL)
(217) (218)
(219) (220)
(221)(178)
(222)(223)
NER Bulky adducts XPA, XPB (ERCC3), XPC, XPD
(ERCC2), XPE (DDB1 & DDB2),
XPF (ERCC4), XPG (ERCC5),
ERCC1, CSA, CSB, TTDA
-Xeroderma Pigmentosum (XP)
-Cockayne Syndrome (CS)
-Trichothiodystrophy (TTD)
(12) (224)
HR DSB BRCA1, BRCA2, NBS1 -Breast, Prostate Cancer
-Nijmegen Breakage Syndrome (NBS)
(225) (226)
BER & SSBR Damaged bases, SSB MUTYH, UNG, OGG1, AAG, APE1,
TDP1, APTX
-MUTYH-Associated, Polyposis (MAP)
-Hyper-IgM syndrome (HIGM) type V
-Lung Cancer
-Spinocerebellar ataxia with axonal
neuropathy 1 (SCAN1)
-Ataxia-oculomotor apraxia 1 (AOA1)
(227)(177)
(228)(157)
(143)
NHEJ DSB DNA-PKcs, Artemis, LigIV,
NHEJ1/XLF/Cernunnos
- Severe Combined Immunodeficiency
(SCID)
(170)(172)
(171)(173)
(169)
FANC Cross-links FANCA, FANCB, FANCC,
FANCD1/BRCA2, FANCD2,
FANCE, FANCF, FANCG, FANCI,
FANCJ/BRIP1, FANCL, FANCM,
FANCN/PALB2, FANCO/RAD51C,
FANCP/SLX4, NBS1
-Fanconi Anemia (FA)
-Nijmegen Breakage Syndrome (NBS)
(182) (226)
(8)
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Table 2
Studies in which DNA repair assays have been used to evaluate human inter-individual and/or tumor-specific
variability in DRC. Publications are categorized by DNA repair pathway studied and the type of assay used.
Black corresponds to studies in which a single repair pathway was assayed. Blue corresponds to studies in
which two or more pathways were assayed as a consequence of a lesion being repaired by more than one
pathway or a protein being involved in more than one pathway. Red corresponds to studies in which two or
more pathways were assayed simultaneously either through sequencing of two or more genes or by the use of
separate repair measurements.
Repair pathway
Evidence of inter-individual/tumor differences in DRC
Indirect measurements
Mutagen Sensitivity
Direct measurements
SNP/GWAS Gene Methylation mRNA Protein Cell free extract Comet HCR
DR (32) (229)
(20) (216)
(54) (55) (56)
(57) (43) (58)
(48)
(230)
(231)
(58)
(231) (64) (66)
(48) (42)
(231) (131)
(7) (52)
(53)
(59) (90)
(229)
MMR (232) (233)
(20) (180)
(232) (63)
(233)
(230)
(57)
(63)
(191)
(63) (234)
(235)
NER (236) (237)
(25) (26)
(120) (28)
(20) (29)
(30) (31)
(70) (72) (238)
(239)
(70)
(230)
(72)
(240)
(70)
(72)
(96) (241) (106) (128)
(238) (110)
(242) (107)
(131) (243)
(108) (120)
(129) (118)
(121) (7)
HR (237) (20) (244) (66)
(69) (245)
(66) (69)
(230)
(69) (89) (98) (99)
(101)
(237) (97)
BER & SSBR (246) (237)
(42) (82)
(20)
(68) (71) (78) (48)
(68)
(230)
(42) (71)
(126)
(71) (79) (246)
(78) (247)
(82) (91)
(142) (92)
(143)
(237) (96)
(100)
(131) (126)
NHEJ (237) (248)
(20) (180)
(69) (69)
(230)
(69) (87) (98) (99)
(101)
(237) (97)
(243) (122)
FANC (67) (249) (244) (64)
(65) (66)
(245)
(65) (66) (64)
(67)
(88) (128) (129)
(7)
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